$9.33▾ 0.64%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 16% below our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
ADMA Biologics Inc's earnings-quality signal is not available yet.
Key numbers
Recent news
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?BTU IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Peabody Energy Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BTU
ADMA 3-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens Berman
MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ADMA